Ms. Celia Economides reports

AURINIA PHARMACEUTICALS TO RELEASE FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS ON MARCH 15, 2018

Aurinia Pharmaceuticals Inc. will release its fourth quarter and full year 2017 financial results on Thursday, March 15, 2018, after the market closes. Aurinia's management will host a conference call to discuss the company's financial results for the fourth quarter and full-year 2017 and provide a general business update.

The conference call and webcast is scheduled for March 15, 2018, at 4:30 p.m. EST. In order to participate in the conference call, please dial 1-877-407-9170 (toll-free United States and Canada). An audio webcast can be accessed under news/events through the investors section of the Aurinia corporate website. A replay of the webcast will be available on Aurinia's website.

About Aurinia Pharmaceuticals Inc.

Aurinia is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS) and dry eye syndrome (DES). The company is headquartered in Victoria, B.C., and focuses its development efforts globally.

We seek Safe Harbor.